Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab in Advanced cSCC and CRPC
NCT06567314Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2024
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in cutaneous squamous cell carcinoma (cSCC), castration-resistant prostate cancer (CRPC), sponsored by University of Texas MD Anderson Cancer Center. Started Dec 2024; status: recruiting.
02
Drugs
ivonescimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT06567314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567314.